Biosimilar Contract Manufacturing Market Size, Trends, Analysis, and Outlook By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disord

Biosimilar Contract Manufacturing Market Size, Trends, Analysis, and Outlook By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Rheumatoid Arthritis, Others), by Region, Country, Segment, and Companies, 2024-2030

The global Biosimilar Contract Manufacturing market size is poised to register 9.38% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Biosimilar Contract Manufacturing market across By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Rheumatoid Arthritis, Others).

The biosimilar contract manufacturing market is experiencing rapid growth, driven by several factors in 2024 and beyond. Biosimilars, which are highly similar versions of approved biologic drugs, offer cost-effective alternatives to branded biologics and are increasingly being adopted worldwide. Contract manufacturing organizations (CMOs) specializing in biosimilars play a crucial role in the production process, offering expertise in cell line development, process optimization, and regulatory compliance. Market growth is fueled by the increasing demand for biosimilars due to rising healthcare costs and the expiration of patents for several blockbuster biologic drugs. Moreover, advancements in bioprocessing technologies and manufacturing platforms are enabling CMOs to enhance production efficiency and reduce costs, driving market expansion. Additionally, strategic partnerships and collaborations between pharmaceutical companies and CMOs are driving innovation and capacity expansion efforts, further propelling market growth. Furthermore, regulatory initiatives aimed at streamlining the approval process for biosimilars are creating opportunities for CMOs to support biosimilar development programs, shaping industry dynamics and competitiveness.

Biosimilar Contract Manufacturing Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilar Contract Manufacturing market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilar Contract Manufacturing survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilar Contract Manufacturing industry.

Key market trends defining the global Biosimilar Contract Manufacturing demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Biosimilar Contract Manufacturing Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Biosimilar Contract Manufacturing industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilar Contract Manufacturing companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Biosimilar Contract Manufacturing industry

Leading Biosimilar Contract Manufacturing companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilar Contract Manufacturing companies.

Biosimilar Contract Manufacturing Market Study- Strategic Analysis Review

The Biosimilar Contract Manufacturing market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Biosimilar Contract Manufacturing Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Biosimilar Contract Manufacturing industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Biosimilar Contract Manufacturing Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Biosimilar Contract Manufacturing Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Biosimilar Contract Manufacturing market segments. Similarly, Strong end-user demand is encouraging Canadian Biosimilar Contract Manufacturing companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Biosimilar Contract Manufacturing market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Biosimilar Contract Manufacturing Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Biosimilar Contract Manufacturing industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Biosimilar Contract Manufacturing market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Biosimilar Contract Manufacturing Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biosimilar Contract Manufacturing in Asia Pacific. In particular, China, India, and South East Asian Biosimilar Contract Manufacturing markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Biosimilar Contract Manufacturing Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Biosimilar Contract Manufacturing Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilar Contract Manufacturing market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilar Contract Manufacturing.

Biosimilar Contract Manufacturing Market Company Profiles

The global Biosimilar Contract Manufacturing market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AGC Biologics, Alcami Corp Inc, Almac Group, Avid Bioservices Inc, Biocon, Boehringer Ingelheim Biopharmaceuticals GmbH, Catalent Inc, Element Materials Technology, Fujifilm Kyowa Kirin Biologics Co. Ltd, IQVIA Inc, Lonza, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc, WuXi Biologics

Recent Biosimilar Contract Manufacturing Market Developments

The global Biosimilar Contract Manufacturing market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Biosimilar Contract Manufacturing Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Product

Recombinant Non-Glycosylated Proteins

Recombinant Glycosylated Proteins

By Production Technology

Mammalian

Non-Mammalian

By Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Chronic and Autoimmune Disorders

Rheumatoid Arthritis

Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies

AGC Biologics

Alcami Corp Inc

Almac Group

Avid Bioservices Inc

Biocon

Boehringer Ingelheim Biopharmaceuticals GmbH

Catalent Inc

Element Materials Technology

Fujifilm Kyowa Kirin Biologics Co. Ltd

IQVIA Inc

Lonza

Rentschler Biopharma SE

Samsung Biologics

Thermo Fisher Scientific Inc

WuXi Biologics

Formats Available: Excel, PDF, and PPT